Sign In
Buy LFCR
$4.42
+0.0600 (+1.38%)
At Close: Jul 31, 2026
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 17'th Jul 2025
CHASKA, Minn., July 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today an
Stock Picks From Seeking Alpha's June 2025 New Analysts
09:00am, Tuesday, 08'th Jul 2025
June saw a record number of 48 new Seeking Alpha analysts, each bringing fresh stock ideas and unique backgrounds to the platform. Analysts provided ratings from Sell to Buy, with detailed justificati
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect
10:00am, Tuesday, 17'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Comp
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer
07:00am, Tuesday, 17'th Jun 2025
CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Comp
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Comp
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
07:00am, Thursday, 12'th Jun 2025
Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation
10:00am, Tuesday, 10'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Comp
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Compa
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Compa
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Compa
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Compa
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Compa
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer
07:00am, Tuesday, 27'th May 2025
Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations
NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Compa
